Description

Proviron 25 mg by Swiss Healthcare contains Mesterolone, an orally active androgen derived from dihydrotestosterone (DHT). It has been historically used in clinical settings to treat male hypogonadism, infertility, and androgen deficiency. In modern research, Proviron is commonly studied for its androgenic support, anti-estrogenic activity, and potential role in enhancing free testosterone levels by reducing sex hormone-binding globulin (SHBG).

Proviron does not convert to estrogen and exhibits no progestogenic activity, making it particularly relevant in studies focused on hormonal balance, libido, and androgen receptor modulation without the risk of estrogenic side effects such as water retention or gynecomastia.

Manufactured to pharmaceutical-grade standards, Proviron is supplied in 50 oral tablets, each containing 25 mg of Mesterolone, ensuring precise dosing for controlled laboratory and analytical research.

Product Details

• Active Ingredient: Mesterolone

• Concentration per Tablet: 25 mg

• Form: Oral tablets

• Package Size: 50 tablets per bottle

Pharmacokinetics

Proviron (Mesterolone) has a relatively short half-life of 12–13 hours and is not 17-alpha alkylated, reducing liver toxicity. It is rapidly absorbed and binds strongly to androgen receptors, with minimal impact on liver enzymes. Its unique profile makes it a favorable oral androgen in studies where liver safety is a concern.

Usage Recommendations

• Typical Research Dosage (historical reference): 25–75 mg per day, divided into 1–3 doses

• Current Use: Intended solely for research and laboratory purposes

• Administration: Oral

Disclaimer

This product is intended strictly for research and laboratory use only. It is not approved for human consumption or therapeutic use. Not suitable for individuals under 18, pregnant or breastfeeding women, or those with hormonal disorders. Use in accordance with all applicable laws and scientific guidelines.